Join us for an R&D Update with Seelos Therapeutics, featuring a discussion on its current pipeline, future directions, and the current treatment landscape and unmet medical needs in neurological diseases/disorders.

Seelos senior management, in conjunction with several Key Opinion Leaders (KOLs), will provide updates on continuing clinical studies, encouraging new preclinical data, recently completed market research, and an overview of the company’s strategic plans across their portfolio of clinical and preclinical stage programs.

For more information on itinerary and speakers, please click here.

About Seelos Therapeutics

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company’s robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD), amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia (SCA), as well as early-stage programs in Huntington’s disease, Alzheimer’s disease, and Parkinson’s disease.

A live Q&A session will follow the formal presentations.